#62 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating older adults need to understand that cannabis use in this population is already widespread despite limited clinical evidence, requiring them to proactively screen for drug interactions and adverse effects that may be particularly pronounced in seniors with polypharmacy. Current policy gaps mean patients lack clear guidance on dosing, product selection, and safety monitoring, leaving clinicians responsible for filling this information void and developing individualized risk-benefit assessments for conditions like chronic pain and insomnia where cannabis is commonly self-prescribed.
Older adults represent a rapidly growing demographic of cannabis users, yet healthcare policy and clinical guidelines have not adequately addressed this population’s specific needs and risks. Seniors are utilizing cannabis primarily for chronic pain, insomnia, and anxiety, conditions that are prevalent in this age group and often lead to substantial healthcare utilization. This gap between actual usage patterns and clinical guidance creates potential safety concerns, as older adults may be self-managing with cannabis while physicians lack evidence-based frameworks for counseling, monitoring, or integration into comprehensive pain and psychiatric care. Clinicians should recognize that many senior patients are already using cannabis and should proactively address this in clinical assessment, particularly given age-related pharmacokinetic changes and increased vulnerability to drug interactions with polypharmacy. The absence of tailored clinical policies and geriatric-specific dosing recommendations limits the ability to optimize therapeutic outcomes while minimizing harm in this vulnerable population. Physicians caring for older adults should develop evidence-based conversations about cannabis use to better understand patient preferences and establish appropriate monitoring protocols until formal guidelines are established.
“What we’re seeing in clinical practice is that older adults are using cannabis effectively for conditions like neuropathic pain and insomnia where conventional medications either don’t work or create worse side effects, yet our healthcare system and regulatory framework haven’t caught up to this reality. Until we integrate cannabis into standard geriatric protocols with proper dosing guidelines and drug interaction screening, we’re essentially asking patients to self-manage a therapy without the clinical support they deserve.”
💊 Cannabis use among older adults is increasingly prevalent, yet clinical guidance and institutional policies have not kept pace with this reality. Providers caring for seniors with chronic pain, insomnia, and anxiety should recognize that many patients may already be using cannabis—whether disclosed or not—and should proactively ask about use to identify potential drug interactions (particularly with sedatives, anticoagulants, and pain medications) and assess for falls, cognitive effects, or other age-related vulnerabilities. The evidence base for cannabis efficacy in these common geriatric conditions remains limited and heterogeneous, with most high-quality trials absent, making risk-benefit discussions challenging. Given that seniors often consume multiple medications and experience altered pharmacokinetics, clinicians should document cannabis use in the medical record, consider referring to geriatric specialists or pain management when appropriate, and advocate within their institutions for evidence-based policies that acknowledge both potential therapeutic applications and genuine safety concerns in this
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: